HOUSE DOCKET, NO. 2016 FILED ON: 1/19/2017
HOUSE . . . . . . . . . . . . . . . No. 1130
|
The Commonwealth of Massachusetts
_________________
PRESENTED BY:
Daniel Cahill
_________________
To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General
Court assembled:
The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:
An Act relative to studying the benefits of single tablet regimen.
_______________
PETITION OF:
Name: | District/Address: | Date Added: |
Daniel Cahill | 10th Essex | 1/19/2017 |
HOUSE DOCKET, NO. 2016 FILED ON: 1/19/2017
HOUSE . . . . . . . . . . . . . . . No. 1130
By Mr. Cahill of Lynn, a petition (accompanied by bill, House, No. 1130) of Daniel Cahill relative to conducting a study regarding the benefits and costs of single tablet regimens or long acting alternative regimens for the treatment of HIV. Public Health. |
The Commonwealth of Massachusetts
_______________
In the One Hundred and Ninetieth General Court
(2017-2018)
_______________
An Act relative to studying the benefits of single tablet regimen.
Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:
SECTION 1. Notwithstanding any general or special rule or law to the contrary, the Department of Public Health shall conduct a study on the overall effectiveness of single tablet regimens or long acting alternative regimens, including but not limited to patch, sub-cutaneous, implantable or intramuscular regimens in comparison to multi-tablet regimens that treat HIV. Said study will conduct an analysis of the costs and benefits of these drug treatments that are medically necessary for the treatment of HIV, including, consistent with clinical guidelines and peer-reviewed scientific and medical literature, if the regimens are clinically equal, which might be more effective and more likely to result in adherence to a drug regimen, how improved adherence may result in increased viral suppression rates, decreased HIV transmission, any cost-savings associated with avoided lifetime medical costs of prevented HIV infections, and which might improve quality of life as it relates to pill burden associated with HIV and other conditions a patient may have.
The Department shall make a report on its findings along with any recommendations for legislative or regulatory improvements to advance their conclusion no later than December 31, 2018.